Levetiracetam (Keppra)
Order Name
LEVETIRACE
Test Number: 3658525
Revision Date 05/28/2021
Test Number: 3658525
Revision Date 05/28/2021
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
Levetiracetam (Keppra)
|
Enzyme Immunoassay | 30471-7 |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 1mL (0.5) | Serum | Clot Activator (Red Top, No-Gel) | Refrigerated |
| Alternate 1 | 1mL (0.5) | Plasma | EDTA (Lavender Top) | Refrigerated |
| Alternate 2 | 1mL (0.5) | Plasma | Sodium Heparin (Green Top / No-Gel) | Refrigerated |
| Instructions | Do not use Gel separation tubes. Separate plasma/serum from cells as soon as possible – prolonged presence of whole blood may cause hydrolysis of Levetiracetam. Stability: Ambient 8 hours, Refrigerated 7 days, Frozen 4 weeks |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon - Fri |
| Expected TAT | 1-3 Days |
| Clinical Use | Brivaracetam (Briviact) interferes with the measurements of Levetiracetam (Keppra) in the ARK Levetiracetam assay. Serum levels of levetiracetam and/or brivaracetam should be confirmed by a valid chromatographic method if there is a possibility these drugs are co-present in circulation. |
| CPT Code(s) | 80177 |
| Internal Comments | 10/18/17 added Briviat interference in test description - JK 12/20/17 added 30471-7 to the test - JK |
| Lab Section | Chemistry |